Topics

FDA refuses to review Nabriva's injectable antibiotic for urinary tract infections

05:51 EDT 1 May 2019 | Pharmafile

Biopharma firm Nabriva Therapeutics has revealed that its antibiotic Contepo (fosfomycin) has been rejected for review by the FDA as an injectable treatment for complicated urinary tract infections (cUTI), including acute pyelonephritis.

According to the manufacturer, Contepo is the first intravenously administered epoxide therapy in the US.

read more

Original Article: FDA refuses to review Nabriva's injectable antibiotic for urinary tract infections

NEXT ARTICLE

More From BioPortfolio on "FDA refuses to review Nabriva's injectable antibiotic for urinary tract infections"

Quick Search

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Urology
Benign Prostatic Hyperplasia (BPH) Erectile Dysfunction Urology Urology is the branch of medicine concerned with the urinary tract and diseases that affect it. Examples include urethritis, urethrostenosis and incontinence. Urology is a su...